FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1994653403> ?p ?o ?g. }

• W1994653403 endingPage "586" @default.
• W1994653403 startingPage "580" @default.
• W1994653403 abstract "We evaluated the efficacy and safety of an oxybutynin transdermal delivery system (TDS) in a general population of patients with overactive bladder and urge or mixed urinary incontinence.Following symptom stabilization or treatment withdrawal 520 adult patients were randomized to 12 weeks of double-blind daily treatment with 1.3, 2.6 or 3.9 mg. oxybutynin TDS or placebo administered twice weekly, followed by a 12-week open-label, dose titration period to assess efficacy and safety further. Evaluations included patient urinary diaries, incontinence specific quality of life and safety.A dose of 3.9 mg. daily oxybutynin TDS significantly reduced the number of weekly incontinence episodes (median change -19.0 versus -14.5, p = 0.0165), reduced average daily urinary frequency (mean change -2.3 versus -1.7, p = 0.0457), increased average voided volume (median change 24 versus 6 ml., p = 0.0063) and significantly improved quality of life (Incontinence Impact Questionnaire total score, p = 0.0327) compared with placebo. Average voided volume increased in the daily 2.6 mg. group (19 ml., p = 0.0157) but there were no other significant differences between 1.3 and 2.6 mg. oxybutynin TDS and placebo. The most common adverse event was application site pruritus (oxybutynin TDS 10.8% to 16.8%, placebo 6.1%). Dry mouth incidence was similar in both groups (7.0% versus 8.3%, p not significant). In the open-label period a sustained reduction of nearly 3 incontinence episodes per day was reported for all groups.Doses of 2.6 and 3.9 mg. oxybutynin TDS daily improve overactive bladder symptoms and quality of life, and are well tolerated. Transdermal oxybutynin is an innovative new treatment for overactive bladder." @default.
• W1994653403 created "2016-06-24" @default.
• W1994653403 creator A5020614716 @default.
• W1994653403 creator A5021309563 @default.
• W1994653403 creator A5037636679 @default.
• W1994653403 creator A5041384721 @default.
• W1994653403 creator A5042646128 @default.
• W1994653403 creator A5051605303 @default.
• W1994653403 creator A5051999453 @default.
• W1994653403 date "2002-08-01" @default.
• W1994653403 modified "2023-10-06" @default.
• W1994653403 title "Efficacy and Safety of Transdermal Oxybutynin in Patients With Urge and Mixed Urinary Incontinence" @default.
• W1994653403 cites W1227345485 @default.
• W1994653403 cites W1410775549 @default.
• W1994653403 cites W1607352979 @default.
• W1994653403 cites W1973454866 @default.
• W1994653403 cites W1982481499 @default.
• W1994653403 cites W1982589773 @default.
• W1994653403 cites W1983918554 @default.
• W1994653403 cites W1986053715 @default.
• W1994653403 cites W1996684801 @default.
• W1994653403 cites W2008079238 @default.
• W1994653403 cites W2011917402 @default.
• W1994653403 cites W2012563222 @default.
• W1994653403 cites W2015584710 @default.
• W1994653403 cites W2016992480 @default.
• W1994653403 cites W2017922615 @default.
• W1994653403 cites W2024975356 @default.
• W1994653403 cites W2026599479 @default.
• W1994653403 cites W2028811068 @default.
• W1994653403 cites W2040008446 @default.
• W1994653403 cites W2053974951 @default.
• W1994653403 cites W2055543772 @default.
• W1994653403 cites W2056759810 @default.
• W1994653403 cites W2057413452 @default.
• W1994653403 cites W2058646317 @default.
• W1994653403 cites W2059946745 @default.
• W1994653403 cites W2069123743 @default.
• W1994653403 cites W2069862149 @default.
• W1994653403 cites W2092079022 @default.
• W1994653403 cites W2094330965 @default.
• W1994653403 cites W2117950925 @default.
• W1994653403 cites W2121173491 @default.
• W1994653403 cites W2127252378 @default.
• W1994653403 cites W2141823090 @default.
• W1994653403 cites W2142419627 @default.
• W1994653403 cites W2148567690 @default.
• W1994653403 cites W2164799400 @default.
• W1994653403 cites W2171846085 @default.
• W1994653403 cites W2399315492 @default.
• W1994653403 doi "https://doi.org/10.1016/s0022-5347(05)64684-8" @default.
• W1994653403 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12131314" @default.
• W1994653403 hasPublicationYear "2002" @default.
• W1994653403 type Work @default.
• W1994653403 sameAs 1994653403 @default.
• W1994653403 citedByCount "192" @default.
• W1994653403 countsByYear W19946534032012 @default.
• W1994653403 countsByYear W19946534032013 @default.
• W1994653403 countsByYear W19946534032014 @default.
• W1994653403 countsByYear W19946534032015 @default.
• W1994653403 countsByYear W19946534032016 @default.
• W1994653403 countsByYear W19946534032017 @default.
• W1994653403 countsByYear W19946534032018 @default.
• W1994653403 countsByYear W19946534032019 @default.
• W1994653403 countsByYear W19946534032020 @default.
• W1994653403 countsByYear W19946534032021 @default.
• W1994653403 countsByYear W19946534032022 @default.
• W1994653403 countsByYear W19946534032023 @default.
• W1994653403 crossrefType "journal-article" @default.
• W1994653403 hasAuthorship W1994653403A5020614716 @default.
• W1994653403 hasAuthorship W1994653403A5021309563 @default.
• W1994653403 hasAuthorship W1994653403A5037636679 @default.
• W1994653403 hasAuthorship W1994653403A5041384721 @default.
• W1994653403 hasAuthorship W1994653403A5042646128 @default.
• W1994653403 hasAuthorship W1994653403A5051605303 @default.
• W1994653403 hasAuthorship W1994653403A5051999453 @default.
• W1994653403 hasConcept C126322002 @default.
• W1994653403 hasConcept C126894567 @default.
• W1994653403 hasConcept C142724271 @default.
• W1994653403 hasConcept C197934379 @default.
• W1994653403 hasConcept C204787440 @default.
• W1994653403 hasConcept C205679159 @default.
• W1994653403 hasConcept C27081682 @default.
• W1994653403 hasConcept C2776312127 @default.
• W1994653403 hasConcept C2777844464 @default.
• W1994653403 hasConcept C2778531004 @default.
• W1994653403 hasConcept C2778941218 @default.
• W1994653403 hasConcept C2908647359 @default.
• W1994653403 hasConcept C2991744798 @default.
• W1994653403 hasConcept C42219234 @default.
• W1994653403 hasConcept C71924100 @default.
• W1994653403 hasConcept C77411442 @default.
• W1994653403 hasConcept C98274493 @default.
• W1994653403 hasConcept C99454951 @default.
• W1994653403 hasConceptScore W1994653403C126322002 @default.
• W1994653403 hasConceptScore W1994653403C126894567 @default.
• W1994653403 hasConceptScore W1994653403C142724271 @default.
• W1994653403 hasConceptScore W1994653403C197934379 @default.

• next